Clinical Trial Search

Primary: Fold Change in Pretomanid AUC(0-last) in Participants With Renal Impairment as Compared to Matched Healthy Controls — 77130; 63600; 62660 ng*h/mL

Primary: Response Rate — 0; 0; 26; 11 Participants

Primary: Percentage of Participants With Response — 0; 15; 65; 10 percentage of participants

Primary: Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) — 259; 293 nanogram per milliliter (ng/mL)

Primary: Number of Patients With a Return of Disease Activity After the Third Month Post-first-infusion — 3; 6 Participants

Primary: Area Under the Plasma Concentration Time Curve (AUC) From Hour 0 to Infinity (AUC[0-inf]) of Gepotidacin for Part 1 — 14838; 22367; 28545 Nanogram*hour per milliliter

Primary: Renal Oxygenation — 22.4; 22.5 s^-1

Primary: Proteinuria — 2.4; 1.6; 1.2; 1.6 g/24hr

Primary: Changes in Renal Blood Flow — 9590.8; 5105.4; 8529.4; 5228.4 h.mL/min

Primary: Overall Response Rate — 72; 35 Percentage of participants

Primary: To Determine the Overall Response Rate of Combination Therapy With Gemcitabine and Sunitinib in Sarcomatoid and/or Poor-risk mRCC Patients as First Line Therapy. — 25…

Primary: Percentage of Participants Who Have a Clinical Response to Treatment (Objective Tumor Regression) — 27.5; 27.1; 19.6; 37.5 Percentage of participants

Primary: Progression-free Survival — 8.3 months

Primary: Maximum Observed Plasma Concentration (Cmax) of PF-07321332 — 1600; 2077; 2210; 2369 Nanogram per milliliter

Primary: Number of All-Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin — 804; 6507; 178334; 1704443 participants — p=0.0002